RU2211704C2 - Модифицированный фактор vii - Google Patents
Модифицированный фактор vii Download PDFInfo
- Publication number
- RU2211704C2 RU2211704C2 RU99100089/14A RU99100089A RU2211704C2 RU 2211704 C2 RU2211704 C2 RU 2211704C2 RU 99100089/14 A RU99100089/14 A RU 99100089/14A RU 99100089 A RU99100089 A RU 99100089A RU 2211704 C2 RU2211704 C2 RU 2211704C2
- Authority
- RU
- Russia
- Prior art keywords
- phe
- arg
- factor vii
- chloromethylketone
- proteinase inhibitor
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- A61K38/166—Streptokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
Abstract
Изобретение относится к медицине, а именно к способам лечения, касающимся улучшения регионального миокардиального кровотока в процессе постишемической реперфузии, а также предупреждения или минимизации повреждений ткани, связанных с постишемической перфузией. Указанное назначение осуществляется путем введения пациенту композиции, которая содержит фармакологически приемлемый Фактор VII, имеющий в своем каталитическом центре по меньшей мере одну модификацию, которая существенно ингибирует способность модифицированного Фактора VII активировать плазменный Фактор Х или IX. Использование Фактора VII, модифицированного указанным образом, позволяет повысить эффективность лечения. 4 с. и 14 з.п. ф-лы, 22 табл., 11 ил.
Description
Текст описания в факсимильном виде (см. графическую часть). Т Тk
Claims (18)
1. Применение Фактора VII, имеющего в своем каталитическом центре по меньшей мере одну модификацию, которая существенно ингибирует способность модифицированного Фактора VII активировать плазменный Фактор Х или IX, для производства композиции для предупреждения или минимизации повреждения ткани, ассоциированного с постишемической реперфузией.
2. Применение по п. 1, где указанная модификация включает в себя взаимодействие Фактора VII с ингибитором сериновой протеиназы.
3. Применение по п. 2, где протеиназным ингибитором является фосфорорганическое соединение, сульфанилфторид, пептидный галогенметилкетон или азапептид.
4. Применение по п. 3, где протеиназным ингибитором является пептидный галогенметилкетон, выбранный из Дансил-Phe-Pro-Arg-хлорметилкетона, Дaнcил-Glu-Gly-Arg-xлopмeтилкeтoнa, Дансил-Phe-Phe-Arg-хлорметилкетона и Phe-Phe-Arg-хлорметилкетона.
5. Применение по пп. 1-4, где повреждение ткани представляет собой некроз.
6. Способ предупреждения или минимизации повреждения ткани, ассоциированного с постишемической реперфузией у индивидуума, включающий в себя введение индивидууму композиции, которая содержит фармакологически приемлемый Фактор VII, имеющий в своем каталитическом центре по меньшей мере одну модификацию, которая существенно ингибирует способность модифицированного Фактора VII активировать плазменный Фактор Х или IX.
7. Способ по п. 6, где модификация включает в себя взаимодействие Фактора VII с ингибитором сериновой протеиназы.
8. Способ по п. 7, где протеиназным ингибитором является фосфорорганическое соединение, сульфанилфторид, пептидный галогенметилкетон или азапептид.
9. Способ по п. 8, где протеиназным ингибитором является пептидный галогенметилкетон, выбранный из Дансил-Phe-Pro-Arg-хлорметилкетона, Дансил-Glu-Gly-Аrg-хлорметилкетона, Дансил-Phe-Phe-Arg-хлорметилкетона и Phe-Phe-Arg-хлорметилкетона.
10. Способ по любому из пп. 6-9, где повреждение ткани представляет собой некроз.
11. Применение Фактора VII, имеющего в своем каталитическом центре по меньшей мере одну модификацию, которая существенно ингибирует способность модифицированного Фактора VII активировать плазменный Фактор Х или IX, для производства композиции для улучшения регионального миокардиального кровотока в процессе постишемической реперфузии.
12. Применение по п. 11, где модификация включает в себя взаимодействие Фактора VII с ингибитором сериновой протеиназы.
13. Применение по п. 12, где протеиназным ингибитором является фосфорорганическое соединение, сульфанилфторид, пептидный галогенметилкетон или азапептид.
14. Применение по п. 13, где протеиназным ингибитором является пептидный галогенметилкетон, выбранный из Дансил-Phe-Pro-Arg-хлорметилкетона, Дансил-Glu-Gly-Аrg-хлорметилкетона, Дансил-Phe-Phe-Arg-хлорметилкетона и Phe-Phe-Arg-хлорметилкетона.
15. Способ улучшения регионального миокардиального кровотока в процессе постишемической реперфузии у индивидуума, включающий в себя введение индивидууму композиции, которая содержит фармакологически приемлемый Фактор VII, имеющий в своем каталитическом центре по меньшей мере одну модификацию, которая существенно ингибирует способность модифицированного Фактора VII активировать плазменный Фактор Х или IX.
16. Способ по п. 15, где модификация включает в себя взаимодействие Фактора VII с ингибитором сериновой протеиназы.
17. Способ по п. 16, где протеиназным ингибитором является фосфорорганическое соединение, сульфанилфторид, пептидный галогенметилкетон или азапептид.
18. Способ по п. 17, где протеиназным ингибитором является пептидный галогенметилкетон, выбранный из Дансил-Phe-Pro-Arg-хлорметилкетона, Дансил-Glu-Gly-Аrg-хлорметилкетона, Дансил-Phe-Phe-Arg-хлорметилкетона и Phe-Phe-Arg-хлорметилкетона.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/660,289 US5833982A (en) | 1991-02-28 | 1996-06-07 | Modified factor VII |
US08/660,289 | 1996-06-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU99100089A RU99100089A (ru) | 2000-11-27 |
RU2211704C2 true RU2211704C2 (ru) | 2003-09-10 |
Family
ID=24648892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU99100089/14A RU2211704C2 (ru) | 1996-06-07 | 1997-06-06 | Модифицированный фактор vii |
Country Status (17)
Country | Link |
---|---|
US (2) | US5833982A (ru) |
EP (1) | EP0910580A1 (ru) |
JP (1) | JP2000513720A (ru) |
KR (1) | KR20000016415A (ru) |
CN (2) | CN1131872C (ru) |
AU (1) | AU735012B2 (ru) |
BR (1) | BR9709661A (ru) |
CA (1) | CA2256761A1 (ru) |
CZ (1) | CZ394698A3 (ru) |
HU (1) | HUP0003077A3 (ru) |
IL (1) | IL127099A0 (ru) |
NO (1) | NO985668L (ru) |
PL (1) | PL330365A1 (ru) |
RU (1) | RU2211704C2 (ru) |
UA (1) | UA68333C2 (ru) |
WO (1) | WO1997047651A1 (ru) |
ZA (1) | ZA975013B (ru) |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5997864A (en) | 1995-06-07 | 1999-12-07 | Novo Nordisk A/S | Modified factor VII |
US20040087498A1 (en) * | 1991-02-28 | 2004-05-06 | Novo Nordisk Health Care Ag | Modified factor VII |
JP2001510168A (ja) * | 1997-07-18 | 2001-07-31 | ノボ ノルディスク アクティーゼルスカブ | FVIIa媒介性細胞内シグナル伝達経路に関連する反対条件の処理のためのFVIIa又はFVIIaiの使用 |
US7247708B2 (en) * | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US6747003B1 (en) * | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US6693075B1 (en) * | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US6406488B1 (en) * | 1998-08-27 | 2002-06-18 | Heartstent Corporation | Healing transmyocardial implant |
EP0987274A1 (en) | 1998-09-15 | 2000-03-22 | Hoechst Marion Roussel Deutschland GmbH | Factor VIIa Inhibitors |
EP1059302A1 (en) | 1999-06-08 | 2000-12-13 | Aventis Pharma Deutschland GmbH | Factor VIIa inhibitors |
US6924359B1 (en) * | 1999-07-01 | 2005-08-02 | Yale University | Neovascular-targeted immunoconjugates |
EP1095933A1 (en) | 1999-10-30 | 2001-05-02 | Aventis Pharma Deutschland GmbH | Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them |
ES2325877T3 (es) * | 2000-02-11 | 2009-09-23 | Bayer Healthcare Llc | Moleculas de tipo factor vii o viia. |
CA2747325A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US7812132B2 (en) | 2000-04-28 | 2010-10-12 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
EP1162194A1 (en) | 2000-06-06 | 2001-12-12 | Aventis Pharma Deutschland GmbH | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use |
WO2001097752A2 (en) * | 2000-06-20 | 2001-12-27 | The Trustees Of The University Of Pennsylvania | Compositions comprising urokinase for modulating muscle contractility and angiogenisis |
US7160540B2 (en) * | 2000-06-30 | 2007-01-09 | Regents Of The University Of Minnesota | Methods for detecting activity of clottings factors |
US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
US6423826B1 (en) | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
BR0115938A (pt) | 2000-12-06 | 2003-12-23 | Aventis Pharma Deustschland Gm | Derivados de guanidina e amidina com inibidores do fator xa |
US6825323B2 (en) * | 2001-01-10 | 2004-11-30 | The United States Of America As Represented By The Secretary Of The Army | Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same |
US7235638B2 (en) | 2001-03-22 | 2007-06-26 | Novo Nordisk Healthcare A/G | Coagulation factor VII derivatives |
ES2432967T3 (es) * | 2001-03-22 | 2013-12-05 | Novo Nordisk Health Care Ag | Derivados del Factor VII de coagulación |
PL366564A1 (en) * | 2001-05-02 | 2005-02-07 | Novo Nordisk A/S | Modified fvii in treatment of ards |
EP1270551A1 (en) | 2001-06-26 | 2003-01-02 | Aventis Pharma Deutschland GmbH | Urea derivatives with antiproteolytic activity |
WO2003022122A2 (en) * | 2001-09-10 | 2003-03-20 | Florence Medical Ltd. | Individual ffr determination for lesions of a multi-lesioned blood vessel |
DK2279755T3 (da) | 2001-10-10 | 2014-05-26 | Ratiopharm Gmbh | Remodellering og glycokonjugering af fibroblastvækstfaktor (FGF) |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
AU2002336920A1 (en) * | 2001-11-02 | 2003-05-12 | Novo Nordisk Health Care Ag | Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis |
EP1314733A1 (en) | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
HUP0402315A3 (en) * | 2001-12-21 | 2009-03-30 | Novo Nordisk Healthcare Ag | Liquid composition of factor vii polypeptides |
KR20040065278A (ko) * | 2001-12-21 | 2004-07-21 | 노보 노르디스크 에이/에스 | 변경된 인자 ⅶ 폴리펩티드의 액체 조성물 |
PL370656A1 (en) * | 2001-12-21 | 2005-05-30 | Novo Nordisk A/S | Liquid composition of modified factor vii polypeptides |
ES2355713T3 (es) * | 2002-04-30 | 2011-03-30 | Bayer Healthcare Llc | Variantes polipeptídicas del factor vii o viia. |
US20040009918A1 (en) * | 2002-05-03 | 2004-01-15 | Hanne Nedergaard | Stabilised solid compositions of modified factor VII |
ATE536886T1 (de) * | 2002-05-03 | 2011-12-15 | Novo Nordisk As | Stabilisierte feste zusammensetzungen von modifizierter faktor vii |
ES2653555T3 (es) | 2002-06-21 | 2018-02-07 | Novo Nordisk Health Care Ag | Composiciones sólidas estabilizadas de polipéptidos del Factor VIIa |
EP1549677B1 (en) * | 2002-09-30 | 2011-04-13 | Bayer HealthCare LLC | FVII OR FVIIa VARIANTS HAVING INCREASED CLOTTING ACTIVITY |
US7358268B2 (en) | 2002-12-04 | 2008-04-15 | Sanofi-Aventis Deutschland Gmbh | Imidazole derivatives as factor Xa inhibitors |
US7429581B2 (en) | 2002-12-23 | 2008-09-30 | Sanofi-Aventis Deutschland Gmbh | Pyrazole-derivatives as factor Xa inhibitors |
US20040176704A1 (en) * | 2003-03-04 | 2004-09-09 | Stevens Timothy A | Collection device adapted to accept cartridge for point of care system |
BRPI0408439A (pt) * | 2003-03-18 | 2006-04-04 | Novo Nordisk Healthcare Ag | composição farmacêutica lìquida aquosa, método para preparar e uso da mesma, método para tratar uma sìndrome responsiva ao fator vii, e, recipiente hermético |
ATE431403T1 (de) * | 2003-03-20 | 2009-05-15 | Bayer Healthcare Llc | Fvii oder fviia varianten |
US7897734B2 (en) * | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
US20070026485A1 (en) | 2003-04-09 | 2007-02-01 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US20040202726A1 (en) * | 2003-04-10 | 2004-10-14 | Deshay Samuel L. | Topical blood pressure composition |
US7317027B2 (en) | 2003-05-19 | 2008-01-08 | Sanofi-Aventis Deutschland Gmbh | Azaindole-derivatives as factor Xa inhibitors |
US7741341B2 (en) | 2003-05-19 | 2010-06-22 | Sanofi-Aventis Deutschland Gmbh | Benzimidazole-derivatives as factor Xa inhibitors |
EP1479677A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | New indole derivatives as factor xa inhibitors |
EP1479675A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Indazole-derivatives as factor Xa inhibitors |
EP1479680A1 (en) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Azaindole derivatives as Factor Xa inhibitors |
US7223780B2 (en) | 2003-05-19 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors |
BRPI0409936A (pt) * | 2003-05-23 | 2006-04-25 | Novo Nordisk Healthcare Ag | uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico |
US7029675B1 (en) * | 2003-06-04 | 2006-04-18 | Shu-Wha Lin | Hepsin antagonist and methods of use |
CA2529828C (en) * | 2003-06-19 | 2013-01-15 | Maxygen Holdings Ltd. | Factor vii or viia gla domain variants |
ES2382157T3 (es) | 2003-06-25 | 2012-06-05 | Novo Nordisk Health Care Ag | Composición líquida de polipépttidos del factor VII |
ES2335994T3 (es) * | 2003-07-01 | 2010-04-07 | Novo Nordisk Health Care Ag | Composicion farmaceutica liquida, acuosa de polipeptidos factor vii. |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
KR20120104619A (ko) * | 2003-08-14 | 2012-09-21 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 인자 vii 폴리펩티드의 액상 수성 약학적 조성물 |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
SI2298287T1 (en) * | 2003-12-19 | 2018-08-31 | Novo Nordisk Health Care Ag | Stabilized compositions of factor VII polypeptides |
EP1568698A1 (en) | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Pyrrole-derivatives as factor Xa inhibitors |
WO2006035058A2 (en) * | 2004-09-29 | 2006-04-06 | Novo Nordisk Health Care Ag | Purification of a drug substance of a factor vii polypeptide by removal of desgla-factor vii polypeptide structures |
DK2586456T3 (en) | 2004-10-29 | 2016-03-21 | Ratiopharm Gmbh | Conversion and glycopegylation of fibroblast growth factor (FGF) |
JP4951527B2 (ja) | 2005-01-10 | 2012-06-13 | バイオジェネリックス アーゲー | 糖peg化顆粒球コロニー刺激因子 |
US20070154992A1 (en) | 2005-04-08 | 2007-07-05 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
WO2008011633A2 (en) | 2006-07-21 | 2008-01-24 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
CA2682897C (en) | 2007-04-03 | 2016-11-22 | Biogenerix Ag | Methods of treatment using glycopegylated g-csf |
MX2009013259A (es) | 2007-06-12 | 2010-01-25 | Novo Nordisk As | Proceso mejorado para la produccion de azucares de nucleotidos. |
PL2257311T3 (pl) | 2008-02-27 | 2014-09-30 | Novo Nordisk As | Koniugaty cząsteczek czynnika VIII |
EP2379096B1 (en) | 2008-12-19 | 2019-10-30 | Baxalta GmbH | Tfpi inhibitors and methods of use |
JP5813641B2 (ja) | 2009-08-24 | 2015-11-17 | アムニクス オペレーティング インコーポレイテッド | 凝固第ix因子組成物ならびにそれを製造および使用する方法 |
CN103025345B (zh) | 2010-03-19 | 2016-01-20 | 巴克斯特国际公司 | Tfpi抑制剂及使用方法 |
KR101294351B1 (ko) * | 2010-05-27 | 2013-08-07 | 동국대학교 산학협력단 | 뇌혈전 형광영상기술을 이용한 뇌졸중 동물모델의 뇌경색 영역의 크기 예측 방법 |
PL3564260T3 (pl) | 2012-02-15 | 2023-03-06 | Bioverativ Therapeutics Inc. | Kompozycje czynnika viii oraz sposoby ich wytwarzania i stosowania |
HUE043537T2 (hu) | 2012-02-15 | 2019-08-28 | Bioverativ Therapeutics Inc | Rekombináns VIII faktor fehérjék |
CN104302306B (zh) | 2012-03-21 | 2019-03-22 | 百深有限责任公司 | Tfpi抑制剂及其使用方法 |
TW202003554A (zh) | 2013-08-14 | 2020-01-16 | 美商百歐維拉提夫治療公司 | 因子viii-xten融合物及其用途 |
BR112018001275A2 (pt) * | 2015-07-22 | 2018-09-18 | Iconic Therapeutics Inc | métodos para tratar transtornos associados à angiogênese e neovascularização |
BR112018002150A2 (pt) | 2015-08-03 | 2018-09-18 | Bioverativ Therapeutics Inc | proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas |
US20190015532A1 (en) | 2016-01-15 | 2019-01-17 | Rigshospitalet | Quantitative pet imaging of tissue factor expression using 18f-labled active site inhibited factor vii |
WO2018091058A1 (en) | 2016-11-17 | 2018-05-24 | Rigshospitalet | 177-lu labeled active site inhibited factor vii |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4775624A (en) * | 1985-02-08 | 1988-10-04 | Eli Lilly And Company | Vectors and compounds for expression of human protein C |
GR860984B (en) * | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
WO1986006408A1 (en) * | 1985-04-22 | 1986-11-06 | Genetics Institute, Inc. | HIGH YIElD PRODUCTION OF ACTIVE FACTOR IX |
US4959318A (en) * | 1985-06-27 | 1990-09-25 | Zymogenetics, Inc. | Expression of protein C |
US4829052A (en) * | 1986-06-11 | 1989-05-09 | Monsanto Company | Serine protease inhibitors |
US5258288A (en) * | 1986-07-25 | 1993-11-02 | Genzyme Corporation | Vector containing DNA encoding mature human protein S |
EP0278727A3 (en) | 1987-02-10 | 1990-03-14 | Glaxo Group Limited | 1-(4-amino-3-chloro-5-trifluoromethylphenyl)-2-(substituted amino)ethanol derivatives and their use in the treatment of respiratory disease |
FR2619314B1 (fr) * | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
US4994371A (en) * | 1987-08-28 | 1991-02-19 | Davie Earl W | DNA preparation of Christmas factor and use of DNA sequences |
US5023236A (en) * | 1988-04-07 | 1991-06-11 | Corvas, Inc. | Factor VII/VIIA active site inhibitors |
US5258180A (en) * | 1988-09-02 | 1993-11-02 | Genetech, Inc. | Tissue plasminogen activator having fibrin specific properties and deletion of amino acids 466-970, compositions and methods of treatment |
EP0391999A4 (en) * | 1988-09-23 | 1991-03-13 | Corvas, Inc. | Peptidyl inhibitors of the initiation of coagulation |
US5120537A (en) * | 1989-06-14 | 1992-06-09 | Oklahoma Medical Research Foundation | Factor xa based anticoagulant compositions |
US5190919A (en) * | 1989-11-13 | 1993-03-02 | Board Of Regents, The University Of Texas System | Antihemostatic factor vii peptides |
ATE180834T1 (de) | 1990-01-29 | 1999-06-15 | Zymogenetics Inc | Antikoagulierende proteine |
US5278144A (en) * | 1990-09-04 | 1994-01-11 | Cor Therapeutics, Inc. | Antithrombosis agents |
US5817788A (en) | 1991-02-28 | 1998-10-06 | Zymogenetics, Inc. | Modified factor VII |
US5861374A (en) | 1991-02-28 | 1999-01-19 | Novo Nordisk A/S | Modified Factor VII |
ATE273393T1 (de) * | 1991-02-28 | 2004-08-15 | Zymogenetics Inc | Modifizierter faktor-vii |
US5788965A (en) | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
US5326559A (en) * | 1991-05-16 | 1994-07-05 | Miller D Douglas | Treatment of accelerated atheosclerosis with interleukin-2 receptor targeted molecules |
US5419760A (en) * | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
GB9301093D0 (en) * | 1993-01-20 | 1993-03-10 | Rca Thomson Licensing Corp | Digital video tape recorder for digital hdtv |
CA2162726A1 (en) * | 1993-05-21 | 1994-12-08 | Kathleen L. Berkner | Modified factor vii |
US5648331A (en) * | 1994-08-26 | 1997-07-15 | G.D. Searle & Co. | Method of inhibiting tissue ischemia and reperfusion injury |
-
1996
- 1996-06-07 US US08/660,289 patent/US5833982A/en not_active Expired - Fee Related
-
1997
- 1997-06-06 UA UA98126442A patent/UA68333C2/uk unknown
- 1997-06-06 WO PCT/DK1997/000251 patent/WO1997047651A1/en not_active Application Discontinuation
- 1997-06-06 JP JP10501082A patent/JP2000513720A/ja not_active Ceased
- 1997-06-06 IL IL12709997A patent/IL127099A0/xx unknown
- 1997-06-06 ZA ZA9705013A patent/ZA975013B/xx unknown
- 1997-06-06 PL PL97330365A patent/PL330365A1/xx unknown
- 1997-06-06 AU AU30906/97A patent/AU735012B2/en not_active Ceased
- 1997-06-06 RU RU99100089/14A patent/RU2211704C2/ru not_active IP Right Cessation
- 1997-06-06 BR BR9709661-0A patent/BR9709661A/pt not_active IP Right Cessation
- 1997-06-06 EP EP97925917A patent/EP0910580A1/en not_active Withdrawn
- 1997-06-06 HU HU0003077A patent/HUP0003077A3/hu unknown
- 1997-06-06 KR KR1019980709998A patent/KR20000016415A/ko not_active Application Discontinuation
- 1997-06-06 CN CN97195294A patent/CN1131872C/zh not_active Expired - Fee Related
- 1997-06-06 CZ CZ983946A patent/CZ394698A3/cs unknown
- 1997-06-06 CA CA002256761A patent/CA2256761A1/en not_active Abandoned
- 1997-06-06 CN CNA031066089A patent/CN1515318A/zh active Pending
-
1998
- 1998-11-10 US US09/189,607 patent/US6168789B1/en not_active Expired - Fee Related
- 1998-12-04 NO NO985668A patent/NO985668L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US6168789B1 (en) | 2001-01-02 |
UA68333C2 (en) | 2004-08-16 |
IL127099A0 (en) | 1999-09-22 |
BR9709661A (pt) | 2000-04-25 |
HUP0003077A2 (hu) | 2000-12-28 |
AU3090697A (en) | 1998-01-07 |
US5833982A (en) | 1998-11-10 |
CZ394698A3 (cs) | 1999-04-14 |
CN1221427A (zh) | 1999-06-30 |
NO985668D0 (no) | 1998-12-04 |
ZA975013B (en) | 1997-12-08 |
CN1515318A (zh) | 2004-07-28 |
EP0910580A1 (en) | 1999-04-28 |
NO985668L (no) | 1999-02-04 |
CN1131872C (zh) | 2003-12-24 |
WO1997047651A1 (en) | 1997-12-18 |
HUP0003077A3 (en) | 2003-01-28 |
JP2000513720A (ja) | 2000-10-17 |
CA2256761A1 (en) | 1997-12-18 |
PL330365A1 (en) | 1999-05-10 |
AU735012B2 (en) | 2001-06-28 |
KR20000016415A (ko) | 2000-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2211704C2 (ru) | Модифицированный фактор vii | |
RU99100089A (ru) | Модифицированный фактор vii | |
Heriot et al. | A review of techniques for liver resection. | |
Wilhelm et al. | Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice | |
EA200500406A1 (ru) | Активный ингибитор серинпротеазы hcv | |
Murkin | Attenuation of neurologic injury during cardiac surgery | |
Hu et al. | Kasabach-Merritt syndrome-associated kaposiform hemangioendothelioma successfully treated with cyclophosphamide, vincristine, and actinomycin D | |
ECSP034493A (es) | Inhibidores de proteasa peptidomimeticos | |
Chauhan et al. | Efficacy of aprotinin, epsilon aminocaproic acid, or combination in cyanotic heart disease | |
Chin | Treatment of maxillary hemangioma with a sclerosing agent | |
Laschinger et al. | Adjunctive left ventricular unloading during myocardial reperfusion plays a major role in minimizing myocardial infarct size | |
Chiu et al. | In vitro and in vivo protective effect of honokiol on rat liver from peroxidative injury | |
WO1996035788A3 (en) | Kunitz type protease inhibitors | |
DK1107737T3 (da) | Mikropartikler til anvendelse ved nålelös injektion | |
US5385885A (en) | Inhibition of smooth muscle cell proliferation by antistasin and tick anticoagulant peptide | |
Pion | Feline aortic thromboemboli and the potential utility of thrombolytic therapy with tissue plasminogen activator | |
Riewald et al. | Treatment options for clinically recognized disseminated intravascular coagulation | |
WO1999063090A3 (en) | Protease inhibitor peptides | |
Sum et al. | Pathogenesis of bile-induced acute pancreatitis in the dog: experiments with detergents | |
Karasawa et al. | Beneficial effects of transforming growth factor-β and tissue plasminogen activator in splanchnic artery occlusion and reperfusion in cats | |
Di Filippo et al. | Hyperthermic isolation limb perfusion with TNFα in the treatment of in-transit melanoma metastasis | |
Stier Jr et al. | Beneficial action of beraprost sodium, a prostacyclin analog, in stroke-prone rats | |
Lung et al. | Hibernoma: report of two cases | |
Li et al. | Evaluation of partial hepatectomy for primary liver carcinoma | |
Fine et al. | Mechanism of action of bacterial endotoxin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20050607 |